Postmenopausal hormone therapy may up your hearing loss risk

A new study has linked the postmenopausal hormone therapy to a higher risk of hearing loss.

Some previous studies suggested that menopause may increase the risk for hearing loss, presumably due to the reduction in circulating estrogen levels, and that postmenopausal hormone therapy might slow hearing decline by 'replacing' estrogen.

To investigate the role of menopause and postmenopausal hormone therapy as risk factors for hearing loss, researchers at Brigham and Women's Hospital prospectively examined the independent links between menopausal status, oral hormone therapy, and risk of self-reported hearing loss in 80,972 women in the Nurses' Health Study II followed from 1991-2013.

During the study period, 23 percent of the participants developed hearing loss. Researchers found no significant overall association between menopausal status and risk of hearing loss, although higher risk was associated with older age at natural menopause. Use of postmenopausal hormone therapy was associated with higher risk of hearing loss, and the risk tended to increase with longer duration of use.

"Many factors contribute to acquired hearing loss, including age, genetics, noise, medical conditions, diet and lifestyle factors," stated lead author Sharon Curhan.

Curhan added, "Our research focuses on identifying preventable contributors to hearing loss. Although the role of sex hormones in hearing is complex and incompletely understood, these findings suggest that women who undergo natural menopause at an older age may have a higher risk. In addition, longer duration of postmenopausal hormone therapy use is associated with higher risk. These findings suggest that hearing health may be a consideration for women when evaluating the risks and benefits of hormone therapy."

The findings are published in Menopause, The Journal of the North American Menopause Society.